Navigation Links
Optim To Assist Prairie Community Health Center with Construction Scope Development
Date:9/10/2007

ROYAL OAK, Mich., Sept. 10 /PRNewswire/ -- Prairie Community Health Center (PCHC), Terry, Montana, has selected Optim to perform an evaluation of hospital renovation, expansion or replacement needs. As the Owner's Representative, Optim will conduct a demographic study of the area's population trends, assess the types of services that PCHC currently provides, and project the services they will need to provide in the years ahead. At the end of the four-week project, Optim will present their findings to PCHC board members, along with several viable program options.

"As rural communities continue to change, Critical Access Hospitals must meet growing demands for healthcare services. Optim understands the challenges that our rural hospitals face. They are specialists in healthcare construction, which has a unique planning process as well as infrastructure requirements," said Reed E. Reyman, Administrator of Prairie Community Health Center.

"Many small hospitals assume that Owner's Representation is a luxury they cannot afford. However, Optim actually saves clients money because we know how to avoid the pitfalls that threaten the success of a major renovation or construction project. We applaud PCHC for taking the time to objectively define their goals and systematically investigate solutions before proceeding with design," said Jeff Larson, Executive Vice President of Optim's Owner's Representation Services.

About Optim

Optim provides innovative solutions that optimize the value of our clients' physical assets. We are the leaders in bringing independent Owner's Representation Services to the healthcare industry. Collectively, our skilled program managers, architects, engineers, and clinical technology experts have over 200 years of experience in meeting the special needs of healthcare organizations.

Optim's incentives are completely tied to the success of our clients' construction projects.

See

SOURCE Optim
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Optimum Timing for HIV/AIDS Prognosis
2. Overdentures: An Optimal Solution To Edentulousness
3. Optimizer(TM) Implant To Treat Heart Failure
4. KPMG Optimistic About Indian Pharma’s Growt
5. Scientist Optimistic In Breakthrough For Causes Of Neurodegenerative Diseases
6. Doctors Optimistic on Separating the Conjoined US Twins
7. Experts Are Optimistic Of Making Waterborne Infectious Diseases A Thing Of Past
8. Salad Contains Nutrients In Optimum Level
9. Optimum Period is Five Years to Treat Osteoporosis: Study
10. WHOs New Chief Very Optimistic
11. Optimum Folate and Vitamin B12 Levels Essential for Cognitive Function in Seniors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)... to have committed patent and ...2 /PRNewswire-FirstCall/ -- Mannatech,Incorporate...r of dietary,supplements and skin care solutions, ...orthern District of Texas found that Glycoproducts...Mannatech,s patent and,trademark relating to Ambro...
(Date:5/12/2008)...Assists Removal of 975 Cardiac ...12 /PRNewswire-FirstCall/ -- Spectranetics,Corpora...reviewed study,demonstrates Spectranetics, excimer...al of pacing and defibrillator leads. The study, "...e with Transvenous Lead,Extraction: Outcomes and C...
(Date:5/12/2008)...g been known that embryonic stem cells have the ab...cells, the exact mechanism as to how this occurs h...ers at the Hebrew University of Jerusalem and else... process, resolving a long-standing question as to...through selective activation or selective repressi...
(Date:5/12/2008)...tCall/ -- ULURU Inc. (Amex: ULU ),today reported ...h 31,2008., For the quarter ended March 31, 2008... was $1,815,000, or $0.03 per share, compared to a... corresponding period in 2007.,The first quarter 2...$497,000, which included stock option expense, amo...
Breaking Medicine News(10 mins):Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 2Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 3Health News:Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal 2Health News:Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal 3Health News:How embryonic stem cells develop into tissue-specific cells demonstrated 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 6
...oman’s reproductive years, usually occurs around a...xperience //early menopause. Early menopause can b...ealth problems, including osteoporosis and cardiov...of Mayo Clinic Women’s HealthSource describes type...
...fits of mammogram screenings because the results a... study by //Yale Public Health researchers in the ... To help reduce death and disability from breast ...of cancer death in American women, current guideli...
...rsity scientists led by Thomas Carpenter, findings...lements for girls, as their effects// would be see...sts carried out a trial on 120 girls aged 8 to 14 ...ium supplements of 300 mg dose and others on a pla...
...ore dispensaries by 2010 to provide better healthc... said Thursday.// She said 365 dispensaries were ... would be set up soon to "enable the common men av...heir doorsteps". The chief minister said her gov...
Other Medicine News:Health News:Inadequate Communication Reduces Benefits of Mammogram Screening for Black Women 2
(Date:5/8/2008)...irstCall/ -- AstraZeneca (NYSE:,AZN) today announc...cation,(sNDA) to the U.S. Food and Drug Administra...e) Extended-Release Tablets to seek approval for t..., including maintenance of,antianxiety effect. It ...atypical antipsychotic medicine in GAD. The submis...
(Date:5/8/2008)... -- Go Healthy (Pink Sheets: GOHE),announces the i...rade (R),in three medical settings with an expecte...ers around the country. Dr. William Bryan of the S... in the Texas Medical Center,will coordinate one c...sician for the Houston Astros and the former Medic...
(Date:5/7/2008)...nduction Dosing Regimen, SEATTLE, May 7 /PRNewswi...daq: TRBN ) today announced that its partner, Wye...E ), has commenced patient dosing in the next,Phas...eumatoid arthritis,(RA). In collaboration with Tru... SBI-087 and other CD20-directed products., The r...
(Date:5/7/2008)...ll/ -- Shire plc (LSE: SHP,Nasdaq: SHPGY), the gl...nounced findings from a new data analysis that was...AYTRANA(TM) (methylphenidate transdermal,system) b...ntion Deficit,Hyperactivity Disorder (ADHD). The f... has an established safety profile and effectively...
Breaking Medicine Technology:AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Go Healthy Initiates Additional Clinical Tests on Cholesterade 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates 767 1Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates 767 2Hemoglobin uncovered 1126 1Hemoglobin uncovered 1126 2Ripe fruit preferred 1124 1Ripe fruit preferred 1124 2Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 1Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 2Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 3Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 4
...SIGA Technologies, Inc.,(NASDAQ: SIGA) announced t...guinea pig trial of its lead Lassa fever virus dru...ty Level 4 conditions at,the U.S. Army Medical Res...by Dr. Kathleen Cashman under the supervision of D...hemorrhagic fever,viruses at USAMRIID for over 12 ...
...drug withdrawal, CHICAGO, May 15, 2007 /PRNewswire... and physicians commissioned by the National,Heada... shows that,20 percent of migraine patients are cu...hat contain barbiturates or opioids and have,not b...ion for the,relief of migraines. , Migraines affec...
Other Medicine Technology:SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 2SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 3SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...
Medicine Products: